Abstract
The measurement of the fetal nuchal translucency thick-ness (NT) combined with maternal age and maternalblood biochemical markers [free beta human chorionicgonadotrophin (free βhCG) and pregnancy-associatedplasma protein A (PAPP-A)] is widely accepted and nowthe most commonly used method for screening Downsyndrome (DS) in the first trimester. Most often, mater-nal blood is taken during the NT visit, and it usuallyrequires a week or two to measure biochemistry andproduce a final report. A one-stop clinic assessment ofrisk model has been proposed, but most clinics do nothave sufficient clinical volume to afford it financially(Spencer
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
